API facility in Visakhapatnam underwent a GMP surveillance inspection by the US FDA from November 3-7, 2025. The inspection resulted in two observations, which Biocon plans to address within the stipulated timeframe. The company stated that these observations are not expected to impact its business operations. Biocon has notified the BSE and NSE about the inspection outcome as part of its regulatory disclosure. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.